Journal article
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Abstract
BACKGROUND: Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain.
METHODS: In this …
Authors
Gerstein HC; Sattar N; Rosenstock J; Ramasundarahettige C; Pratley R; Lopes RD; Lam CSP; Khurmi NS; Heenan L; Del Prato S
Journal
New England Journal of Medicine, Vol. 385, No. 10, pp. 896–907
Publisher
Massachusetts Medical Society
Publication Date
September 2, 2021
DOI
10.1056/nejmoa2108269
ISSN
0028-4793